Gara Jalqabaatti › Saree Oljoo › Oregon › Portland
Qorannoo klinikaalii Saree Oljoo Portland, OR keessatti
Qorannoo 33 Saree Oljoo f Portland fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.
Takkalaa qorannoo (Ingiliffa)
Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Namoota walitti qabaa jiraSadarkaa 3
- Oregon Health & Science University, Knight Cancer Institute, Portland
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Namoota walitti qabaa jiraSadarkaa 1/2
- Oregon Health & Science University (OHSU), Portland
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
Namoota walitti qabaa jiraSadarkaa 3
- Northwest Cancer Specialists, Portland
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Namoota walitti qabaa jiraQorannoo ilaalaaHojjettoota fayyaa simatamoo
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Providence Willamette Falls Medical Center, Oregon City · Miili 12 fagaatti
A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer
Namoota walitti qabaa jiraSadarkaa 1/2
- Compass Oncology - Rose Quarter Cancer Center, Portland
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
Namoota walitti qabaa jiraSadarkaa 1
- Research Site, Portland
Study of AVZO-021 in Patients With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Avenzo Therapeutics Recruiting Site, Portland
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Namoota walitti qabaa jiraSadarkaa 3
- Providence Portland Medical Center ( Site 0044), Portland
- Providence St. Vincent Medical Center ( Site 0081), Portland
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
Namoota walitti qabaa jiraSadarkaa 2
- Oregon Health and Science University, Portland
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Providence Portland Medical Center, Portland
- Providence St. Vincent Medical Center, Portland
- Local Institution - 0052, Portland
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
Namoota walitti qabaa jiraSadarkaa 3
- Clinical Trial Site, Portland
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Namoota walitti qabaa jiraSadarkaa 3
- Oregon Health and Science University, Portland
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
Namoota walitti qabaa jiraSadarkaa 2
- Providence Portland Medical Center, Portland
- Providence St. Vincent Medical Center, Portland
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
Namoota walitti qabaa jiraSadarkaa 3
- Providence Portland Medical Center, Portland
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Namoota walitti qabaa jiraSadarkaa 3
- Providence Cancer Institute Franz Clinic, Portland
- Providence Cancer Institute Franz Clinic, Portland
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Providence Portland Medical Center, Portland
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Namoota walitti qabaa jiraSadarkaa 1
- Providence Cancer Institute, Portland
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Namoota walitti qabaa jiraSadarkaa 3
- Providence Portland Medical Center, Portland
- Providence Oncology and Hematology Cancer Clinic - Westside;Investigation Drug Services Pharmacy, Portland
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Namoota walitti qabaa jiraSadarkaa 3
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Kaiser Permanente Northwest, Portland
- fi 2 dabalataa
A Study of MGC026 in Participants With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Providence Cancer Institute, Portland
E-Mindfulness Approaches for Living After Breast Cancer
Namoota walitti qabaa jiraSadarkaa 3
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Kaiser Permanente Northwest, Portland
- fi 1 dabalataa
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Namoota walitti qabaa jiraSadarkaa 1/2
- Compass Oncology - Rose Quarter, Portland
Identifying and Caring for Individuals With Inherited Cancer Syndrome
Namoota walitti qabaa jiraHojjettoota fayyaa simatamoo
- Providence Portland Medical Center, Portland
- OHSU Knight Cancer Institute, Portland
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Providence Cancer Institute Franz Clinic, Portland
177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer
Namoota walitti qabaa jiraSadarkaa 2
- OHSU Knight Cancer Institute, Portland
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Namoota walitti qabaa jiraSadarkaa 2
- Oregon Health & Science Institute (OHSU), Portland
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Namoota walitti qabaa jiraSadarkaa 3
- Legacy Good Samaritan Hospital and Medical Center, Portland
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- fi 1 dabalataa
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Namoota walitti qabaa jiraQorannoo ilaalaa
- Kaiser Permanente Northwest, Portland
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Namoota walitti qabaa jiraQorannoo ilaalaaHojjettoota fayyaa simatamoo
- Oregon Health Sciences University, Portland
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Namoota walitti qabaa jiraQorannoo ilaalaa
- Massive Bio SYNERGY-AI site, Portland
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
Namoota walitti qabaa jiraSadarkaa 3
- Kaiser Permanente Northwest, Portland
- Oregon Health and Science University, Portland
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
Namoota walitti qabaa jiraQorannoo ilaalaa
- Legacy Good Samaritan Medical Center, Portland
EMBRACE: Exercising Together
Namoota walitti qabaa jiraSadarkaa 2Hojjettoota fayyaa simatamoo
- OHSU Knight Cancer Institute, Portland
Qorannoo Saree Oljoo magaalota biroo keessatti
- New York City, NYQorannoo 136
- Houston, TXQorannoo 126
- Boston, MAQorannoo 112
- Nashville, TNQorannoo 81
- Los Angeles, CAQorannoo 73
- Edison, NJQorannoo 68
- St. Louis, MOQorannoo 64
- Queens, NYQorannoo 64
- Durham, NCQorannoo 64
- Chicago, ILQorannoo 59
- Philadelphia, PAQorannoo 56
- Dallas, TXQorannoo 55
Qorannoo biroo Portland keessatti
- Kansara Qara'a Non-Small CellQorannoo 46
- Saree (Gosoota Hunda)Qorannoo 34
- Kansarii ProstateQorannoo 33
- Kansara MetastatikiiQorannoo 29
- Kansarii ColorectalQorannoo 28
- Kansarii OvariiQorannoo 27
- Dhibee QaraQorannoo 26
- Leukemia Myeloidii HamaaQorannoo 25
- Kansa EndometiriyaaliiQorannoo 24
- Kansa Selii Skwaamoo Mataa fi MormaQorannoo 19
- Kansarii PancreasQorannoo 19
- Cufama OnneeQorannoo 17
Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.